The FDA granted a positive review for an acute myeloid leukemia drug trial, with initial dosing expected in 2025.

More information: Stefanie Weiss et al, Atovaquone and selinexor as a novel combination treatment option in acute myeloid ...

However, we found that most acute myeloid leukemia (AML) cells, especially M4 and M5 subtypes, produce TNF and show basal level activation of RIP1/RIP3/MLKL signaling, yet do not undergo necroptosis.